European Heart Journal - Cardiovascular Pharmacotherapy · 2020 · 30 citations · 30 references
MedicineCardiologyPharmacotherapyCardiovascular PharmacotherapyClinical PharmacologyMeta-analysisAntiplatelet TherapyClinical TrialsCoronary Artery DiseaseNetwork Meta-analysisStent PlacementThrombosisAntiplatelet Therapy After Percutaneous Coronary InterventionAntithrombotic Therapy After Stent ImplantationBayesian Network Meta-analysisIn-stent ThrombosisPrimary Efficacy EndpointsSafety Endpoint AnalysisSafety Endpoint AssessmentSecondary Efficacy Endpoints
AIMS: To compare the safety and efficacy of very short (≤3 months), short (6 months), standard (12 months), and extended (>12 months) dual antiplatelet therapy (DAPT), and of subsequent monotherapies, after coronary drug-eluting stent (DES) implantation. METHODS AND RESULTS: Twenty-two randomized control trials (n = 110 059 patients/year) were selected and included in a Bayesian network meta-analysis. The primary efficacy endpoint (PEP) was a composite of cardiac death, myocardial infarction (MI), and stent thrombosis (ST), with each of the components of the PEP being a secondary efficacy endpoint. The primary safety endpoint was major bleeding rate. Compared to standard, we found a lower rate of MI [odds ratio (OR) 0.56, 95% confidence interval (CI) 0.44-0.77] in extended, a lower rate of major bleeding (OR 0.61, 95% CI 0.39-0.87) in very short, and a lower rate of any bleeding (OR 0.61, 95% CI 0.38-0.90) in short DAPT. All DAPT durations were comparable regarding the secondary efficacy endpoints. Very short DAPT followed by P2Y12 inhibition was the treatment of choice to reduce both major bleeding and MI. In the ACS subgroup, extended DAPT (as compared to standard) reduced PEP and ST rates (but not MIs). CONCLUSION: The efficacy of short and very short is comparable with that of standard DAPT after DES implantation, whereas extended DAPT reduces MI rate. Very short DAPT is associated with lower haemorrhagic events and, followed by a P2Y12 inhibitor monotherapy, should be preferred in order to pursue a trade-off between major bleeding and ischaemic events.
30
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins, Doug Altman, Peter C Gøtzsche et al. · BMJ · 2011 · 34.2K citations · Full text
Brian Hutton, Georgia Salanti, Deborah M Caldwell et al. · Annals of Internal Medicine · 2015 · 8.1K citations
2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes
Juhani Knuuti, William Wijns, Antti Saraste et al. · European Heart Journal · 2019 · 7.1K citations · Full text
2018 ESC/EACTS Guidelines on myocardial revascularization
Franz‐Josef Neumann, Miguel Sousa‐Uva, Anders Ahlsson et al. · European Heart Journal · 2018 · 7.1K citations · Full text
Early and Sustained Dual Oral Antiplatelet Therapy Following Percutaneous Coronary Intervention
Steven R. Steinhubl, Peter B. Berger, J. Tift Mann et al. · JAMA · 2002 · 3.1K citations